GFAP and Alzheimer disease: A strength of this study is that it is the first formally planned systematic review and meta-analysis to comprehensively evaluate the existing evidence on the blood biomarker GFAP based on longitudinal cohort studies for prognosticating presymptomatic individuals and those with early AD.